Balyasny Asset Management LLC Altimmune, Inc. Transaction History
Balyasny Asset Management LLC
- $61.9 Billion
- Q2 2025
A detailed history of Balyasny Asset Management LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 100,000 shares of ALT stock, worth $362,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,000
Previous 54,953
81.97%
Holding current value
$362,000
Previous $274,000
41.24%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ALT
# of Institutions
222Shares Held
36.5MCall Options Held
4.92MPut Options Held
4.18M-
Black Rock Inc. New York, NY5.32MShares$19.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.17MShares$18.7 Million0.0% of portfolio
-
State Street Corp Boston, MA2.75MShares$9.97 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$9.96 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA1.93MShares$7 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $177M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...